Listed by the USPTO as SKELDING, ZACHARY S
Tech Center 1600 • Art Units: 1600 1644 1674
This examiner grants 60% of resolved cases
Zachary S. Skelding serves in Tech Center 1600 and Art Unit 1600, where he has handled 835 resolved cases. The allowance rate is 59.8 percent, suggesting a balanced environment for patent applicants. This rate is paired with a median days to allowance of 1331, which serves as a benchmark for the duration of the prosecution process.
The interview lift is 41.1 percent, indicating that direct engagement with the examiner provides a significant boost to the 59.8 percent baseline allowance rate. This lift can be a decisive factor in resolving outstanding issues and securing a patent. Practitioners should factor the 1331-day median duration into their strategic planning when considering an interview.
Top companies such as Amgen Inc., University of Leicester, and Genmab A/S are active in this examiner's caseload. These applicants are supported by firms like NELSON MULLINS RILEY & SCARBOROUGH LLP, Knobbe, Martens, Olson & Bear, LLP, and Neal, Gerber & Eisenberg LLP. With 835 resolved cases, the examiner's statistics offer a reliable basis for predicting outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18184860 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Non-Final OA | Novartis AG |
| 18046865 | METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES | Final Rejection | Genentech, Inc. |
| 18142129 | GLYCOENGINEERING | Non-Final OA | The General Hospital Corporation |
| 17921794 | PHARMACEUTICAL FORMULATION | Final Rejection | AMGEN INC. |
| 17775386 | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules | Final Rejection | AMGEN INC. |
| 18314577 | Single chain binding molecules comprising N-terminal ABP | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 16586318 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 18474631 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | Non-Final OA | University of Leicester |
| 18355871 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | Non-Final OA | University of Leicester |
| 18312891 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | Non-Final OA | University of Leicester |
| 18109708 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | Non-Final OA | Genmab A/s |
| 16582428 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | Non-Final OA | GENMAB A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.8% of resolved applications examined by Zachary S Skelding were allowed (835 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +41.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Zachary S Skelding took 1,331 days on average from filing to allowance.
Zachary S Skelding examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
